Malaysia Announces Voluntary Pharmacovigilance Inspections From Jan 2023
Executive Summary
The Malaysian drug agency is inviting drug companies to voluntarily sign up to its new risk-based pharmacovigilance inspection program so that they can build and strengthen their internal systems before such inspections become mandatory.
You may also be interested in...
Roche’s Eye Drug Scores First UK Approval Under Access Consortium
The UK MHRA has approved its first drug under an international work-sharing initiative that also includes regulators from Australia, Canada, Singapore and Switzerland.
UK MHRA Specifies Eligibility For Consultancy Firms To Monitor GMP, GDP Compliance
Consultancy firms must have at least five years of experience in carrying out independent GMP or GDP audits if they want to apply to become a “compliance monitor” under a new MHRA scheme to keep track of drug companies that fail to comply with GMP/GDP requirements.
Digital Data Deluge Can Affect Oversight Of Patient Safety In Trials
The digitalization of clinical trials is generating more patient safety data than companies can process. A senior EMA official says sponsors should carefully select what is needed to maintain appropriate subject oversight by “getting the science right.”